ProCE Banner Activity

CME

Advances in Early-Stage Urothelial Cancer: Expert Guidance for a New Treatment Algorithm

Multimedia

Watch this interactive recording of a live CCO webinar to hear expert perspectives on incorporating neoadjuvant and adjuvant therapy in management of NMIBC along with the latest data on upper tract urothelial cancer.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: October 04, 2021

Expiration: October 03, 2022

No longer available for credit.

Share

Faculty

Seth P. Lerner

Seth P. Lerner, MD

Professor of Urology
Beth and Dave Swalm Chair in Urologic Oncology
Vice Chair,
Faculty Affairs
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Jean Hoffman-Censits

Jean Hoffman-Censits, MD

Assistant Professor
Department of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Surena Matin

Surena Matin, MD

Professor
Division of Surgery
Department of Urology
MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

UroGen

Target Audience

This program is intended for urologists and other healthcare professionals (HCPs) who care for patients with UC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with UTUC most likely to benefit from primary chemoablation therapy relative to ureteronephrectomy
  • Select appropriate treatment for patients with NMIBC that is unresponsive to BCG
  • Describe the proper technique for instillation of chemoablation therapy with reverse thermal gel in patients with early-stage UC
  • Critically appraise the risks and benefits of available and emerging intravesical therapies and immunotherapies relative to early cystectomy in patients with NMIBC
  • Refer patients with early-stage UC for enrollment on clinical trials investigating novel therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Seth P. Lerner, MD

Professor of Urology
Beth and Dave Swalm Chair in Urologic Oncology
Vice Chair,
Faculty Affairs
Scott Department of Urology
Baylor College of Medicine
Houston, Texas

Seth P. Lerner, MD, has disclosed that he has received consulting fees from Aura, Bristol-Myers Squibb, C2i Genomics, FerGene, Genentech, Merck, Pfizer/EMD Serono, QED, Stimit, UroGen, Vaxiion, and Verity and funds for research support from Endo, FKD Therapies, JBL (SWOG), QED, UroGen, Vaxiion, and Viventia.

Faculty Disclosure

Primary Author

Jean Hoffman-Censits, MD

Assistant Professor
Department of Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Jean Hoffman-Censits, MD, has disclosed that she has received consulting fees and funds for research support from Seattle Genetics and fees for non-CME/CE services from Genentech.

Surena Matin, MD

Professor
Division of Surgery
Department of Urology
MD Anderson Cancer Center
Houston, Texas

Surena Matin, MD, has disclosed that he has received consulting fees from Johnson & Johnson and Merck, fees for non-CME/CE services from UroGen, and funds for research support from QED.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 04, 2021, through October 03, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with early-stage UC.